@article{ATM12031,
author = {Jennifer L. Wilkinson-Berka and Devy Deliyanti},
title = {The potential of anti-VEGF (Vasotide) by eye drops to treat proliferative retinopathies},
journal = {Annals of Translational Medicine},
volume = {4},
number = {Suppl 1},
year = {2016},
keywords = {},
abstract = {Ocular neovascularization and vascular leakage are major causes of vision loss and blindness and hallmark features of retinopathy of prematurity (ROP), proliferative diabetic retinopathy (PDR) and neovascular age-related macular degeneration (AMD) (1-3). These diseases comprise a significant global health burden. For instance, it is predicted that by 2035 over 592 million people will be diagnosed with diabetes and by 2040 around 288 million individuals will have AMD (4,5).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/12031}
}